Hemostasis in COVID-19
Keywords:SARS-CoV-2, COVID-19, Pulmonary embolism, Thromboprophylaxis, Thrombosis
Patients with severe COVID-19 pneumonia are at high risk of thrombotic complications related to coagulopathy induced by CoV-2-SARS, which worsens their prognosis. The pathophysiological mechanisms of this coagulopathy include endothelial dysfunction partly explained by a hyperinflammatory state and the resulting activation of coagulation. Current methods for assessing hemostasis do not seem to be enough to evaluate this thrombotic over-risk and the thromboprophylaxis goals probably needs to be increased.